Study Title

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Study Number

GI011

Enrollment status

Open

Categories

Pancreatic, Unresectable - Locally Advanced

Study Summary

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.

Study Coordinator(s)

  • Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
  • Jessica, 309-243-3615, jjones@illinoiscancercare.com
  • Kimberley, 309-243-3618 ksinanan@illinoiscancercare.com

Study Link

View Study Details

Additional Information

RT Credentialed at OSF (Glen Oak and Route 91)